



OPPORTUNITIES AND CHALLENGES IN TRANSLATING CELL AND GENE THERAPY PRODUCTS

SEPTEMBER 4-5, 2019 • HILTON LONDON TOWER BRIDGE, LONDON, UK



Wednesday, September 4, 2019

7:30 am – 9:30 am	AAPS Registration
8:30 am – 8:45 am	Welcome and Overview Sanyogitta Puri, Ph.D., AstraZeneca
8:45 am – 12:00 pm	Session One: General Overview & Introduction to Cell and Gene Therapy Products Globally and in the UK/EU
8:45 am	Cells, Genes Proteins and Peptides for Active Immune Therapy of Cancer Professor Farzin Farzaneh, Ph.D., FRCPath, Kings College London
9:30 am	General Introduction to Cell and Gene Therapy Therapeutics Johan Hyllner, Ph.D., AstraZeneca AB
10:15 am	Coffee Break
10:30 am	Gene Therapy for Cystic Fibrosis: Update and Lessons Learned Eric Alton, MD, FRCP, FMedSci, Imperial College London
11:15 am	AV Delivery In Utero Anna L. David, BSc (Hons), MB ChB, Ph.D., FRCOG, University College London
12:00 pm – 1:15 pm	Networking Lunch with Group Discussions
	Lunch and Learn Presentation: How to Overcome Analytical Challenges of Cell and Gene Therapy Safety Studies <i>Brought to you by:</i> Charles River Philippe Ancian, Ph.D., Charles River

1:15 pm – 4:30 pm	Session Two: Breakthrough in Discovery and Technology Innovations for Cell and Gene Therapy Products Preclinically
1:15 pm	Viromers for Gene Editing in vivo Steffen Panzner, Ph.D., Lipocaelyx
2:00 pm	Improving in vivo Gene Delivery Approaches Gaurav Sahay, Ph.D., Oregon State University
2:45 pm	Developing Preclinical Packages for ATMPs Michaela Sharpe, Ph.D., Cell and Gene Therapy Catapult
3:30 pm	Coffee Break
3:45 pm	Collaborate to Innovate – Capability Creation via Collaborative Innovation Daniel C. Smith, Ph.D., FRSB, Cobra Biologics
4:30 pm – 5:00 pm	Panel Discussion Moderator: Annette Bak, Ph.D., MBA, AstraZeneca
5:00 pm – 6:00 pm	Networking Reception

Thursday, September 5, 2019

7:30 am – 9:30 am	AAPS Registration
8:30 am – 8:45 am	Welcome and Reflections Chad Briscoe, Ph.D., PRA Health Sciences
8:45 am – 12:00 pm	Session Three: Preclinical to Clinical Translation Studies /Testing Cascade
8:45 am	Lentiviral Vector Manufacture – From Clinical to Commercial James Miskin, Ph.D., Oxford BioMedica
9:30 am	ADA-SCID Gene Therapy: From Bench to Biotech Pervinder Sagoo, Ph.D., Orchard Therapeutics
10:15 am	Coffee Break
10:30 am	Preclinical Safety Assessment of CRISPR/Cas9 Therapeutics Mick Fellows, Ph.D., AstraZeneca
11:15 am	Preclinical to Clinical Translation of CAR Product

	Stefanos Theoharis, Ph.D., Cell Medica
12:00 pm – 1:00 pm	Networking Lunch
1:00 pm – 4:45 pm	Session Four: Towards Late Clinical Development
1:00 pm	Ensuring Successful Adoption of Advanced Therapies – ATTC model Claire Brady, Ph.D., Cell and Gene Therapy Catapult
1:45 pm	Vein to Vein Logistics in Clinical Trials for Cell Therapy Cassandra Moran, DO, MS, PRA Health Sciences
2:30 pm	Bioanalytical Overview of Cell and Gene Therapeutics with focus on qPCR in Clinical Trials Robert Dodge, Ph.D., Novartis
3:15 pm – 3:30 pm	Coffee Break
3:30 pm	Applications of Flow Cytometry in Clinical Trials of Cell Therapy Henko Tadema, Ph.D., PRA Health Sciences
4:15 pm	ATMP Manufacture; Current and Future Perspective Matthew Cobb, Ph.D., Miltenyi Biotec Ltd
5:00 pm – 5:15 pm	Closing Remarks